Form 4: Quest Diagnostics SVP, Clinical Solutions, Karthik Kuppusamy, Reports Stock Sale

Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics, reported the sale of 2,555 shares of common stock at $170 per share on April 2, 2025, according to a Form 4 filing.

Summary

• Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on April 2, 2025.
• Mr. Kuppusamy sold 2,555 shares of Quest Diagnostics common stock at a price of $170 per share.
• Following the transaction, Mr. Kuppusamy directly owns 10,575 shares of common stock.
• He also indirectly owns 358 shares through a trust and 1,613 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a stock sale by an executive, which is a routine occurrence. The sale was conducted under a pre-arranged plan, further reducing any potential negative interpretation.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's value and future prospects. It is important to note that this is a single transaction by one executive and may not be indicative of broader trends.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders if it influences the stock price, although the sale was conducted under a pre-arranged plan.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates

Keywords

Form 4, Quest Diagnostics, Karthik Kuppusamy, Stock Sale, Beneficial Ownership, DGX, SEC Filing